By using our website, you are agreeing to cookies being stored and Google Analytics being used on your device in order to offer the best possible service. You can find more information on thishere.
Austria.
Dynamic Business Location.

Apeiron Biologics gets a EUR 25 million loan from EIB

Apeiron CEO H. Loibner © Apeiron Biologics

The funds are designed to help the company develop new pharmaceutical products for the treatment of cancer, especially rare types affecting children. The financing for Apeiron was made possible by the “European Fund for Strategic Investments” (EFSI).

Apeiron was founded in 2003 by the geneticist Josef Penninger, the scientific director of the Institute for Molecular Biology (IMBA) in Vienna. In May 2017, the European Commission granted market approval for a therapy focusing on immunotherapy of neuroblastoma. The therapy should increase the survival and chances of recovery for the serious cancer neuroblastoma which affects children at an early age. It is a rare cancer, but is responsible for up to 10% of solid tumors in childhood, affecting about 1,200 children in the EU and USA every year.  

Share on Facebook Share on Facebook Share on Twitter Share on Twitter Share on Linkedin Share on Linkedin

Testimonials

Events

Meet us at events, seminars and trade shows - worldwide.

  • China International Fair for Investment & Trade

    08.09. - 11.09. 2020, Xiamen, China

  • Finanzgipfel 2020

    17.09.2020/ 08:00 , Frankfurt, Deutschland

Austria Map

Find the perfect location for your company

Austria stands out due to its long-term reliable and stable conditions. These features are particularly important for a research-based company such as Boehringer Ingelheim. Furthermore, Vienna is a city with a good research infrastructure and a high quality of life, and is thus also an interesting place for highly qualified employees from Austria and abroad.

Boehringer Ingelheim

Logo
More testimonials

news from the business location Austria

Novartis extends penicillin production in Tyrol

The Swiss pharmaceutical company Novartis decides on location Austria and invests 2.5 Billion EURO into penicillin production.

“Cash or card?” - Austria, the coronavirus pandemic and the increasing trend towards cashless payment.

The number of cashless transactions in Austria has been increasing for years. This upward trend once again experienced a tremendous boost due to the coronavirus pandemic.

More news All blog posts